|
[posting]60842899[/posting] Valuation: €460m (€18.72/share) We value Medigene at €460m (€18.72/share) vs €470m (€19.16/share). We now include the Roivant/Cytovant deal in our valuation and have updated our launch timelines for MDG1011. We have also rolled our model forward and updated for FX. |
|
| aus der Diskussion: | Medigene / Gegenwart und Zukunft |
| Autor (Datum des Eintrages): | Zimtzicke (21.06.19 12:34:57) |
| Beitrag: | 48,487 von 51,475 (ID:60860527) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |